LABU Direxion Daily S&P Biotech Bull 3X Shares
Quote as of Oct 09, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 223.00 | Day Range | 223.71 – 246.22 |
| 52-Week Range | 102.35 – 341.93 | Volume | 605.18K |
| Avg Volume | 473.54K | AUM | $597.1M (Oct 10, 2026) |
| Expense Ratio | 0.96% | Yield (TTM) | 0.37% |
| NAV | 223.27 | Premium/Discount | +8.88% indicative |
| Inception | May 28, 2015 | Holdings | 156 |
| Issuer | Direxion | Exchange | AMEX |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 25460G120 | ISIN | US25460G1206 |
| Structure | Leveraged 3x | ||
| Management | Passive / index-tracking (per issuer description) | ||
About this ETF
Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF is an exchange traded fund launched by Direxion Investments. It is managed by Rafferty Asset Management, LLC. It invests in public equity markets of the United States. It invests directly, through derivatives and through other funds in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. It uses derivatives such as futures, swaps to create its portfolio. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track 3x the daily performance of the S&P Biotechnology Select Industry Index. Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF was formed on May 28, 2015 and is domiciled in the United States.
Description from the fund data provider · profile as of Oct 10, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | -12.88% | -17.27% | +40.80% | +52.51% | +117.01% | +49.92% | -25.24% | -11.78% | -20.14% |
| Total return | -12.88% | -17.27% | +40.80% | +52.51% | +118.14% | +50.74% | -24.97% | -11.54% | -19.95% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 09, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.96% | Annual cost of a $10,000 investment | $96.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 173 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | SPSIBI SWAP ASSET LEG (SPSIBICTL) | — | 15.92% | 26.46K | $309.3M |
| 2 | SPSIBI SWAP ASSET LEG (SPSIBIUBL) | — | 15.47% | 25.72K | $300.6M |
| 3 | SPSIBI SWAP ASSET LEG (SPSIBIMLL) | — | 14.09% | 23.42K | $273.8M |
| 4 | SPSIBI SWAP ASSET LEG (SPSIBIBCL) | — | 11.19% | 18.60K | $217.4M |
| 5 | SPSIBI SWAP ASSET LEG (SPSIBIJPL) | — | 9.48% | 15.77K | $184.3M |
| 6 | GOLDMAN FINL SQ TRSRY INST 506 | — | 6.66% | 129.34M | $129.3M |
| 7 | SPSIBI SWAP ASSET LEG (SPSIBIBPL) | — | 1.28% | 2.13K | $24.9M |
| 8 | DREYFUS GOVT CASH MAN INS | — | 1.04% | 20.25M | $20.3M |
| 9 | SPSIBI SWAP ASSET LEG (SPSIBIGSL) | — | 0.83% | 1.39K | $16.2M |
| 10 | MODERNA INC | MRNA | 0.53% | 52.01K | $10.2M |
| 11 | TWIST BIOSCIENCE CORP | TWST | 0.44% | 56.19K | $8.5M |
| 12 | NATERA INC | NTRA | 0.43% | 21.35K | $8.3M |
| 13 | ABBVIE INC | ABBV | 0.39% | 28.11K | $7.7M |
| 14 | UNITED THERAPEUTICS CORP | UTHR | 0.38% | 13.91K | $7.4M |
| 15 | AMGEN INC | AMGN | 0.38% | 18.02K | $7.3M |
| 16 | BIOGEN INC | BIIB | 0.38% | 33.47K | $7.3M |
| 17 | HALOZYME THERAPEUTICS INC | HALO | 0.37% | 65.67K | $7.2M |
| 18 | IOVANCE BIOTHERAPEUTICS INC | IOVA | 0.37% | 536.96K | $7.1M |
| 19 | EXELIXIS INC | EXEL | 0.37% | 120.91K | $7.1M |
| 20 | GILEAD SCIENCES INC | GILD | 0.37% | 48.42K | $7.1M |
| 21 | TG THERAPEUTICS INC | TGTX | 0.35% | 129.05K | $6.9M |
| 22 | VERTEX PHARMACEUTICALS INC | VRTX | 0.35% | 13.53K | $6.8M |
| 23 | PROTAGONIST THERAPEUTICS INC | PTGX | 0.35% | 48.38K | $6.8M |
| 24 | KRYSTAL BIOTECH INC | KRYS | 0.34% | 20.26K | $6.6M |
| 25 | CRISPR THERAPEUTICS AG | CRSP | 0.34% | 129.65K | $6.5M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.37% | Paid (last 12 months) | $0.9097 |
| Frequency | Quarterly | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Dec 23, 2025 | Last payment | $0.9097 (Dec 31, 2025) |
| Growth 1Y | +112.13% | Growth 3Y / 5Y (ann.) | +335.68% / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 23, 2025 | Dec 23, 2025 | Dec 31, 2025 | $0.9097 |
| Sep 23, 2025 | Sep 23, 2025 | Sep 30, 2025 | $0.1027 |
| Jun 24, 2025 | Jun 24, 2025 | Jul 01, 2025 | $0.2190 |
| Mar 25, 2025 | Mar 25, 2025 | Apr 01, 2025 | $0.1071 |
| Jun 25, 2024 | Jun 25, 2024 | Jul 02, 2024 | $0.1502 |
| Mar 19, 2024 | Mar 20, 2024 | Mar 26, 2024 | $0.1606 |
| Dec 21, 2023 | Dec 22, 2023 | Dec 29, 2023 | $0.2097 |
| Sep 19, 2023 | Sep 20, 2023 | Sep 26, 2023 | $0.0020 |
| Jun 21, 2023 | Jun 22, 2023 | Jun 28, 2023 | $0.0090 |
| Dec 23, 2019 | Dec 24, 2019 | Dec 31, 2019 | $0.0050 |
| Sep 24, 2019 | Sep 25, 2019 | Oct 01, 2019 | $0.0110 |
| Jun 25, 2019 | Jun 26, 2019 | Jul 02, 2019 | $0.0370 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 85.18% / 83.94% | Sharpe 1Y / 3Y | 2.63 / 1.34 |
| Max drawdown 1Y / 3Y | -34.71% / -78.30% | Sortino 1Y | 4.10 |
| Beta vs S&P 500 (3Y) | 3.06 | Correlation vs S&P 500 (1Y) | 0.436 |
| Downside deviation 1Y | 54.71% | Risk-free rate used | 4.05% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 11, 2026. Formulas →
Liquidity
| Volume today | 605.18K | Average volume | 473.54K |
| AUM | $597.1M | Premium/Discount | +8.88% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $9.4K | 0.00% | $597.1M → $597.1M |
| 1 Month | $111.2M | +21.29% | $522.3M → $597.1M |
| 1 Week | $19.6M | +3.31% | $590.9M → $597.1M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for LABU
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.